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Derepression of DUX4 in skeletal muscle has emerged 
as a likely cause of pathology in facioscapulohumeral 
muscular dystrophy (FSHD). Here we report on the use 
of antisense phosphorodiamidate morpholino oligo-
nucleotides to suppress DUX4 expression and function 
in FSHD myotubes and xenografts. The most effective 
was phosphorodiamidate morpholino oligonucleotide 
FM10, which targets the polyadenylation signal of DUX4. 
FM10 had no significant cell toxicity, and RNA-seq anal-
yses of FSHD and control myotubes revealed that FM10 
down-regulated many transcriptional targets of DUX4, 
without overt off-target effects. Electroporation of FM10 
into FSHD patient muscle xenografts in mice also down-
regulated DUX4 and DUX4 targets. These findings dem-
onstrate the potential of antisense phosphorodiamidate 
morpholino oligonucleotides as an FSHD therapeutic 
option.
Received 22 March 2016; accepted 18 May 2016; advance online  
publication 5 July 2016. doi:10.1038/mt.2016.111
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD)1 and 2 are 
genetic diseases whose primary manifestations are weakness and 
wasting of muscles of the face, shoulder girdle, and upper arms. 
FSHD1, representing ~95% of cases, is associated with dele-
tions of macrosatellite D4Z4 repeats in the subtelomeric region 
of chromosome 4q35, leaving 1–10 D4Z4 repeats.1 FSHD2 is in 
most cases associated with mutations in Structural Maintenance 
Of Chromosomes Flexible Hinge Domain Containing 1 (SMCHD1) 
on chromosome 18 (ref. 2). Both of these mutations lead to 
relaxation of chromatin at the 4q35 D4Z4 repeat array, allowing 
aberrant transcription in muscle of a full-length form of DUX4 
mRNA (DUX4-fl), which encodes a double homeobox transcrip-
tion factor.2–6 Development of laboratory animal models of FSHD 
have been challenging, due in part to the unknown pathophysi-
ologic mechanism of DUX4 action and the restricted emergence 
of the D4Z4-DUX4 chromosomal architecture in primates and 
Afrotheria.7,8 Nevertheless, the evidence that DUX4 is an FSHD 
disease gene is compelling, including the findings that: (i) both 
FSHD1 and 2 are associated with particular “permissive” 4q35A 
haplotypes that include a polyadenylation signal required for 
production of stable DUX4-fl mRNA from the telomeric D4Z4 
repeat; (ii) overexpression of DUX4-fl induces a large cohort of 
germline genes that are also up-regulated in FSHD muscle5,9,10; 
and (iii) overexpression of full-length DUX4 protein is toxic in 
muscle, both in vitro and in vivo.11,12
These findings identify DUX4 as a promising therapeutic target 
for antisense therapy. Antisense oligonucleotides are being devel-
oped as therapeutics for other neuromuscular diseases including 
Duchenne muscular dystrophy, spinal muscular atrophy (SMA) 
and myotonic dystrophy.13–16 Here we report a proof-of-concept 
study of the therapeutic potential of antisense phosphorodiami-
date morpholino oligonucleotides (PMOs) for the treatment of 
FSHD, by targeting DUX4 and demonstrating efficacy in both 
FSHD myogenic cells and human muscle xenografts.
RESULTS
Transcriptome sequencing (RNA-seq) was performed on cultured 
myotubes derived from the biceps of 6 FSHD subjects and their 
unaffected first-degree relatives to establish a reference transcrip-
tional signature (detailed later in this section). Consistent with 
previous studies,10 FSHD myotubes expressed elevated levels of 
direct and indirect transcriptional targets of DUX4 (ref. 9). The 
mRNA levels of DUX4 targets serve as biomarkers of DUX4 activ-
ity, and can be more readily quantified than levels of DUX4 mRNA 
or DUX4 protein, which are often quite low (ref. 9 and  Materials 
and Methods).
PMOs that target the DUX4-fl transcript (Figure 1a and 
Supplementary Table S1) were tested for their ability to sup-
press the expression of DUX4 protein and selected DUX4 target 
genes.17–19 Differentiating myotube cultures derived from FSHD 
subjects were treated for 4 days with control or DUX4 PMOs, and 
then analyzed for biomarker expression to assay knockdown effi-
ciency. FM10 and, to a lesser extent, FM9 had the greatest effects, 
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consistently decreasing levels of DUX4 target genes ZSCAN4, 
MBD3L2, and TRIM43 (Figure 1b and Supplementary Figure S1), 
establishing that these compounds block DUX4 function. Notably, 
FM10 targets the same 25-nucleotide sequence as PMO-PAS, 
one of two PMOs (of five tested) that showed highest efficacy in 
knocking down DUX4 expression in a recent independent study by 
Marsollier et al.20 Both FM10 and FM9 target the polyadenylation 
signal region of the DUX4 transcript. The other PMOs tested in this 
series, which target regions 5′ of those two, did not decrease bio-
marker expression. None of the PMOs disrupted expression of myo-
sin heavy chain 1, a marker of myogenic cell differentiation (Fig. 1 
and Supplementary Figure S1). FM10 down-regulation of DUX4 
target genes in FSHD cells was dose-dependent, with ED50 (the dose 
required to achieve 50% of FSHD biomarker knockdown) in the 
range 1–3 µmol/l, and maximal response between 10–20 µmol/l 
(see Supplementary Figure S2). Cell viability assays performed 
on FSHD cells treated with FM10 morpholinos conjugated to a cell 
penetrating peptide, Peptide B (PPMO;21), revealed no toxicity at 
concentrations up to 500 µmol/l (see Supplementary Figure S3).
PMO effects on protein levels of DUX4 were evaluated in con-
trol and DUX4 PMO-treated FSHD myotube cultures by immu-
nostaining with an antibody targeting a C-terminal region in the 
full-length DUX4 protein that is absent from the alternatively 
spliced “short” DUX4, which is not thought to be a toxic protein.5 
DUX4-positive nuclei were reduced in FM9-treated myotubes 
and almost undetectable in FM10-treated myotubes (Figure 1c), 
establishing their inhibition of DUX4 protein expression.
Transcriptomes of FSHD and control myotube cultures treated 
with FM10 or standard control PMO were determined by RNA-seq. 
P-value < 10−4 was used as the cutoff for significance in tests of 
differential expression. In myotube cultures from two FSHD sub-
jects, 47 genes differed significantly between FM10 versus control 
PMO treatment, with an associated false discovery rate of 0.066 
(Figure 2b and Supplementary Table S2). Of these 47 genes, 
46 had lower expression with FM10 treatment than with control 
PMO.
To assess whether these changes reflected a suppression of 
FSHD-associated transcription, we compared PMO transcrip-
tome results to the RNA-seq data from myotubes of six FSHD 
subjects versus their unaffected relatives, in which 121 genes 
were significantly upregulated in FSHD and four were signifi-
cantly downregulated (false discovery rate = 0.021; Figure 2a and 
Supplementary Table S3), and to the 213 DUX4 targets from 
Supplementary Table S1 of Yao et al.,10 which includes 94 of the 
121 genes significantly upregulated in FSHD versus unaffected 
myotubes. Both false positives and false negatives have a sto-
chastic component (including sampling error), which limits how 
well sets of significantly altered genes from different studies will 
agree, even for identically designed and equally powered studies 
(which these are not). As a more relaxed measure of agreement, 
though still subject to sampling error, we checked whether the sig-
nificantly altered genes in one study were changed in a consistent 
direction in the other study, regardless of significance. About 89% 
of the genes that were significantly reduced with FM10 had at least 
Figure 1  DUX4 and DUX4 target gene knockdown in facioscapulohumeral muscular dystrophy (FSHD) myotubes in vitro. (a) Schematic dem-
onstrating DUX4-fl transcript and relative targets of phosphorodiamidate morpholino oligonucleotides (PMOs); PAS, polyadenylation signal. (b) FSHD 
biomarker expression analysis of 4-day FSHD myotube cultures treated with standard control or DUX4-targeting morpholinos. Significant decreases 
in CCNA1, MBD3L2, TRIM43, and ZSCAN4 biomarker expression were observed in myotube cultures treated with 10 umol/l FM10 (*P-value < 0.05, 
Student’s t-test performed on ΔCts normalized to RPL13A); an intermediate effect was observed in FM9-treated cultures. MYH1 expression was not 
affected by PMO treatment. Data are presented as the mean fold change ± standard error of mean (SEM) relative to standard control morpholino. (c) 
DUX4 protein expression analysis of 4-day FSHD myotube cultures treated with standard control or DUX4-targeting morpholinos. DUX4 protein was 
detected by immunostaining with C-terminal DUX4-specific P4H2 antibody. The greatest decrease in DUX4-positive nuclei was observed in myotube 
cultures treated with 10 umol/l FM10; an intermediate effect was observed in FM9-treated cultures.
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some upregulation in FSHD myotubes, and conversely 96% of the 
genes that were significantly upregulated in FSHD myotubes had 
at least some reduction with FM10 (Figure 2a,b). The reduction 
was not typically to the level of DUX4 targets observed in con-
trol cells: many DUX4 targets were elevated more than 16-fold 
in FSHD versus unaffected myotubes (log2 fold-change > 4 in 
Figure 2a), whereas few showed more than four-fold decrease by 
FM10 versus control PMO (log2 fold-change < −2 in Figure 2b), 
and this is not because the two FM10-treated FSHD samples had 
particularly low levels of the DUX4 targets pretreatment (see 
Supplementary Figure S4).
RNA-seq analysis of FM10 myotube cultures from the two 
unaffected first-degree relatives provides another view of off-tar-
get effects, unclouded by DUX4 target genes, as unaffected cells 
express little if any DUX4-fl. For these cells, only three genes dif-
fered significantly between FM10 and the control PMO (P-value < 
10–4), and this is roughly what one expects by chance when testing 
~37,000 genes for differential expression, even if the null hypoth-
eses of equal expression are all true (Figure 2c). No genes had 
P-value < 10−5 or false discovery rate < 0.72. Thus we observed no 
clear off-target effects of FM10 based on these samples.
We evaluated FM10 PMO knockdown of DUX4-fl in human 
muscle in vivo using an FSHD xenograft model created by 
transplanting FSHD affected donor muscle into the hindlimbs of 
NOD-Rag1nullIL2rγnull immunodeficient mice.22 Engrafted muscle 
from FSHD biopsy donors and FSHD autopsy donors regener-
ated and was revascularized and reinnervated by 4 months post-
transplant. Importantly, DUX4-fl as well as DUX4 target gene 
expression in these xenografts has been shown to mirror those 
of the donor muscle tissue.22 FM10 or standard control PMO was 
electroporated into FSHD xenografts, and mice were analyzed 
after 2 weeks (Figure 3a). Human xenografts were confirmed by 
immunohistochemistry using antihuman spectrin and antihuman 
lamin a/c antibodies to stain specifically for human muscle fiber 
membranes and human nuclei, respectively (Figure 3b). In FSHD 
xenografts, FM10 reduced DUX4-fl expression to nearly unde-
tectable levels compared with control PMO (Figure 3c). FM10 
treatment also reduced the expression of DUX4 target genes 
MBD3L5 and ZSCAN4 in xenografts compared with control PMO 
(Figure 3d).
DISCUSSION
Our study provides proof-of-concept that antisense PMO targeted 
specifically to the essential DUX4 polyadenylation signal can sig-
nificantly diminish the expression of DUX4-fl and DUX4 target 
genes that serve as biomarkers of DUX4 activity,5,23,24 both in vitro 
Figure 2 RNA-seq analysis of facioscapulohumeral muscular dystrophy (FSHD) versus unaffected myotube cultures and FM10 versus con-
trol phosphorodiamidate morpholino oligonucleotide (PMO)-treated myotube cultures. These volcano plots show log2(fold-change) versus 
-log10(P-value) for tests of differential expression of ~ 37,000 genes detected by RNA-seq, for three comparisons: (a) myotube cultures from FSHD 
subjects versus unaffected first-degree relatives (n = 6 pairs); (b) FM10 versus control (CTRL) PMO-treated myotube cultures from FSHD subjects 
(n = 2); and (c) FM10 versus control (CTRL) PMO-treated myotube cultures from unaffected subjects (n = 2). The two subjects in b are first-degree 
relatives of the two subjects in c, and are unrelated to the 12 subjects in a. To aid in comparisons between plots, the color-coding of points in all 
plots is determined by direction and significance of changes in a: genes whose expression is higher in FSHD than control myotubes are colored red 
if P-value < 10−4 and pink otherwise; genes whose expression is lower in FSHD than control myotubes are colored blue if P-value < 10−4 and light 
blue otherwise. In all plots, black squares are overlaid on the DUX4 targets from Table S1 of Yao et al. 10 Of the 46 genes that were significantly 
decreased by FM10 in b, 41 had elevated expression in FSHD versus control myotubes in a, significantly so for 32; and 30 were among the DUX4 
targets from Table S1 of Yao et al.10 Conversely, 116 of the 121 genes that were significantly elevated in FSHD versus unaffected myotubes in a, and 
162 of the 185 detected DUX4 target genes from Table S1 of Yao et al.10 had at least some reduction by FM10 in b. P-values are from likelihood-
ratio tests for negative binomial regression (R package edgeR), and prior counts of 1 were used to avoid infinite log fold-changes; see Materials and 
Methods for details.
40
35
30
25
20
−
lo
g 1
0 
(p-
va
lue
)
−
lo
g 1
0 
(p-
va
lue
)
−
lo
g 1
0 
(p-
va
lue
)
15
10
5
0
20
15
10
5
0
−6 −4 −2 0
Log2 (fold–change)
FSHD/unaffected myotubes
Higher in FSHD, P < 10−4
Higher in FSHD, P ≥ 10−4
Lower in FSHD, P ≥ 10−4
Lower in FSHD, P < 10−4
DUX4 target (Yao et al.)
No difference
2 4 6
10
5
0
−6 −4 −2 0
Log2 (fold–change)
FM10/CTRL in unaffected myotubes
FM10/CTRL in FSHD myotubes
2 4 6
−6 −4 −2 0
Log2 (fold–change)
2 4 6
a b
c
Molecular Therapy vol. 24 no. 8 aug. 2016 1407
Official journal of the American Society of Gene & Cell Therapy
DUX4 Antisense Therapeutics for FSHD
and in human xenografted muscle in vivo. Previously, PMOs and 
other antisense oligonucleotides targeting 3′  elements of DUX4-fl, 
including splice acceptor sites 2 and 3 and the polyadenylation 
signal, have been shown to reduce expression of DUX4 and select 
DUX4 targets in vitro.20,25 Our in vitro studies provide a global 
view of transcriptional changes associated with DUX4 knock-
down, and provide experimental data on off-target effects that 
complement in silico predictions. In particular, the 25-nucleotide 
sequence targeted by FM10 is the same as that targeted by PMO-
PAS in Marsollier et al., which did not have strong off-target can-
didates based on a Basic Local Alignment Search Tool (BLAST) 
search and predictions of binding energies.20 Differences in dose 
response results observed here and by Marsollier et al. are likely 
due to use of different timing and methods of PMO delivery: 
Marsollier et al. transfected leash-PMO cationic complexes at day 
2 of differentiation20; in our hands, we found that lipid transfec-
tion was quite toxic to our cells (data not shown), and therefore 
elected to simply treat cells with naked PMO without lipid starting 
at day 0 of differentiation.
Our studies of FM10 PMO also evaluate its cell toxicity and 
in  vivo effect on DUX4, which are essential in pursuing thera-
peutic development. Future studies will be needed to evaluate 
the efficacy of repeated and systemic administration of PMOs in 
knocking down DUX4 target gene expression, and although the 
pathophysiology of FSHD remains incompletely understood, we 
anticipate that one or more of these DUX4 target genes is respon-
sible for FSHD muscle weakness and could serve as a direct thera-
peutic target. Our findings, therefore, provide comprehensive 
evidence that antisense PMO technology is a potential therapeutic 
option for FSHD.
Figure 3 In vivo validation of FM10 knockdown of DUX4-fl and DUX4 target genes in a human facioscapulohumeral muscular dystrophy 
(FSHD) xenograft model. (a) Schematic of the in vivo study design. FSHD patient muscle was transplanted into the tibialis anterior space of NRG 
mice. Xenografts fully regenerated in the mouse leg for more than 4 months, were treated with Control- or FM10- phosphorodiamidate morpholino 
oligonucleotides (PMO) via electroporation, and harvested after 2 weeks. (b) Histology of a four-month FSHD xenograft. Immunohistochemistry of 
the human-specific muscle membrane protein spectrin and nuclear envelope protein lamin A/C confirmed that the xenograft was well regenerated. 
Human spectrin (red), human lamin A/C (green), DAPI (blue). Scale bar: 200 μm. (c) Expression analysis of DUX4-fl and (d) of DUX4 target genes 
MBD3L5 and ZSCAN4 in xenografts from biopsy and autopsy donor groups, all with FSHD, treated with Control- and FM10-PMOs. Statistical tests 
were performed on ΔCts, normalized to housekeeping genes PPIA and GUSB. Significant decreases were observed for all three genes with FM10 treat-
ment (**P < 0.01; *P < 0.05, all tests two-tailed). No correlation was detected between housekeeping gene expression and treatment. The biopsy 
group consisted of xenografts from three FSHD donors (n = 4 Ctrl; n = 6 FM10); to address between-donor rather than within-donor variance in 
response to FM10, ΔCts for xenografts from each donor were averaged, and a paired t-test performed on the per-donor averages. All xenografts in 
the autopsy group were from a single FSHD donor (n= 10 Ctrl; n = 6 FM10), and an unequal variance t-test was used for this data. Expression levels 
for each xenograft are shown as fold-changes relative to the per-donor mean ΔCt for the Ctrl PMO (2−ΔΔCt), with mean of the per-donor averages 
(biopsy) or mean ± standard error of mean (SEM) (autopsy) also indicated.
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MATERIALS AND METHODS
Human subjects, genotyping, and biopsy. This study was approved by 
the Johns Hopkins School of Medicine Institutional Review Board. The 
Declaration of Helsinki Protocols was followed, and written informed con-
sent was received from participants prior to inclusion in the study. Subjects 
with FSHD and their first degree unaffected relatives were recruited and 
screened for biomaterial contributions. FSHD status was determined by 
pulsed field electrophoresis and southern blotting of leukocyte DNA by Dr. 
Steven A. Moore and the University of Iowa Diagnostic Laboratories, Iowa 
City, IA, and included identification of the EcoRI/BlnI 4q35 D4Z4 repeat 
length with a p13E11 probe, and 4qA/4qB allele typing of HindIII frag-
ments.26–29 Subjects with a positive FSHD diagnosis were categorized with 
an A, B or C designation, and unaffected control subjects with a confirmed 
negative genotype were categorized with a U, V, or W designation. Open 
muscle biopsy was performed on biceps from living donors and deltoid 
muscle was harvested from autopsy.30 Clinical data for subjects 33A, 33U, 
41A, 58A, 61A, and 61B are presented in Supplementary Table S4; data 
for remaining subjects were published previously.30,31
Morpholinos. PMOs were synthesized by Gene Tools, LLC (Philomath, 
OR), with a 5’ primary amine modification to facilitate conjugation 
with a cell penetrating peptide (CPP) Peptide B21; PMOs conjugated to 
Peptide B are abbreviated as PPMOs. Sequences of PMOs are shown in 
Supplementary Table S1.
Cell culture and in vitro morpholino treatment. Primary muscle cells from 
FSHD subjects 03A, 13B, 14A, 15A, 15B, 16A, 17A, 18A, 21A, 33A, 41A 
and first-degree, unaffected relatives 03U, 13U, 14W, 16U, 21U, and 33U 
were cultured as previously described.32 To assess PMO activity, cells were 
cultured until >95% confluent, rinsed briefly with PBS (Cellgro Mediatech, 
Massasas, VA), and then differentiated in Opti-MEM (Invitrogen, Carlsbad, 
CA) supplemented with 10 µmol/l DUX4-targeting PMO or standard con-
trol PMO (Gene Tools, LLC). The standard control PMO designed by Gene 
Tools, LLC targets a human beta-globin intron mutation that causes beta-
thalassemia, and this target is restricted to beta-thalessemic hematopoi-
etic cells (www.gene-tools.com). Cells were treated with PMOs for 4 days 
without a medium change, and then harvested for quantitative real-time 
PCR (qPCR) analysis or immunocytochemistry. To identify ED50 of FM10, 
cells were cultured as above and treated with 0–15 µmol/l standard con-
trol or FM10 PMO for 4 days and assayed for qPCR analysis. Toxicity was 
assessed with 17A primary muscle cells treated with 0–500 µmol/l standard 
control or FM10 PPMOs conjugated to CPP Peptide B21 in triplicate, using 
the Celltiter-Glo Luminescent Viability Assay (Promega, Madison, WI) 
according to manufacturer’s instructions. Fluorescence was measured using 
a Tecan Safire II plate reader operated by Xfluor4 Software v4.51.
Antibodies and immunostaining.  Myotube cultures treated with DUX4-
targeting PMOs or standard control PMOs were fixed with 4% formalde-
hyde, pH 7.4 (EMD, Billerica, MA) and immunostained with C-terminal 
specific mouse-anti-DUX4 clone P4H2 (kindly provided by Drs. Stephen 
Tapscott and Linda Geng) as previously described.31 Secondary detection 
was performed using the ABC Elite kit (Vector Labs, Burlingame, CA) and 
3,3-diaminobenzidine (DAB) peroxidase staining. DUX4-positive nuclei 
were counted using DIC microscopy, and total number of nuclei was esti-
mated by counting 10 random fields and multiplying by a factor account-
ing for area screened. Muscle cryosections (10 μm) were fixed in ice-cold 
methanol (Thermo Fisher Scientific, Waltham, MA), blocked with anti-
mouse IgG (MKB-2213, Vector Labs) for 2 hours, incubated in the primary 
antibodies for 1 hour (antihuman spectrin (NCL-SPEC1, Leica, Wetzlar, 
Germany, 1:50) and antihuman lamin A/C (Ab40567, AbCam, Cambridge, 
UK, 1:200)), followed by 45 minute incubation with secondary antibod-
ies (AlexaFluor 488 goat antimouse IgG1, AlexaFluor 594 goat antimouse 
IgG2b (Invitrogen, Carlsbad, CA, 1:500)] at room temperature. All nuclei 
were labeled with 4’,6-diamidino-2-phenylindole (DAPI) in mounting 
medium (P36930, Invitrogen).
RNA isolation, cDNA synthesis, and qPCR analyses. RNA was isolated 
from cells or xenografts as previously described.4,5 cDNA was synthesized 
using Oligo (dT)16 and Superscript III reverse transcriptase (Invitrogen). 
Primers were synthesized by Integrated DNA Technologies, Coralville, IA. 
Primer sequences are listed in Supplementary Table S5. Cell qPCR reac-
tions were set up in triplicate using iQ SYBR Green Supermix (Bio-Rad, 
Hercules, CA) and amplified on a CFX96 Touch Real-time PCR Detection 
System (Bio-Rad). Results were analyzed using CFX Manager Software, 
and visualized graphically using Microsoft Excel and Graphpad Prism 6. 
Expression was normalized to RPL13A, which was found to not change 
significantly in response to any PMO or PPMO treatment. From the xeno-
grafts, DUX4-fl expression was determined using 100 ng of poly(A)+ cDNA 
by qPCR as described previously.33 qPCR reactions were performed using 
Taqman Master Mix (Bio-Rad) with specific Taqman assays for ZSCAN4 
(Hs00537549_m1, Life Tech, Carlsbad, CA), MBD3L5 (Hs04190573_mH, 
Life Tech), GUSB (Hs99999908_m1, Life Tech) and PPIA (Hs99999904_
m1, Life Tech) and run on a CFX PCR machine  (Bio-Rad). Reactions were 
set up in duplicate. Statistical tests were performed on ΔCts, normalized to 
the mean Ct of PPIA and GUSB. The samples where DUX4 was not detected 
were given a Ct of 45 (total cycle number). The control PMO-treated biopsy 
group included two 58A, one 61A and one 61B xenograft, and the FM10-
PMO biopsy group included three 58A, one 61A, and two 61B xenografts. 
To address between-donor rather than within-donor variance in response 
to FM10, multiple xenografts from the same donor in each treatment were 
averaged at the ΔCt level, then these average levels were used in the paired 
t-tests of control PMO versus FM10. Autopsy xenografts (n = 10 Ctrl and 
n = 6 FM10) were from a single donor, and were analyzed with a two tailed 
t-test, assuming unequal variance.
RNA sequencing and analysis.  High throughput TruSeq stranded 
mRNA sequencing (RNA-seq, 50- or 51-bp paired end) was performed 
by Expression Analysis, Morrisville, NC. To identify differences between 
FSHD and unaffected muscle cells, sequencing was performed on 4-day 
differentiated myotube cells from FSHD subjects 03A, 13B, 14A, 16A, 
21A, and 33A; and their first-degree, unaffected relatives 03U, 13U, 14W, 
16U, 21U, and 33U (respectively). To identify effects of FM10 PMO treat-
ment (both DUX4-dependent and off-target effects), 4-day myotubes from 
FSHD subjects 15A and 17A, and first degree, unaffected relatives, 15V 
and 17U (respectively), treated with FM10, standard-control morpholino, 
or Opti-MEM medium alone were sequenced. Samples from 17A and 17U 
were treated and sequenced in duplicate, which allows estimation of within- 
subject variance in response to treatment, but the statistical tests reported 
here depend on between-subject variance in response to treatments, and 
use just the first replicate so that all subjects are treated uniformly (Data 
from both replicates is shown in Supplementary Figure S4). FASTQ files 
of raw RNA-seq reads were mapped to Ensembl human GRCh37 reference 
genome and transcript annotations (version 7.5) from Illumina iGenomes 
using TopHat2 (2.1.0)34 and Bowtie2 (2.2.6)35 with options -r 70 –mate-std-
dev 40 for the FSHD versus unaffected data and -r 60 –mate-std-dev 40 for 
the PMO data (which was done later and had a bit shorter average insert 
length). Counts of reads mapping unambiguously to ~63,000 annotated 
genes were computed using htseq-count (HTSeq-0.6.1p1, strand-specific 
mode),36 and imported into R for tests of differential expression using the 
package edgeR (3.12).37 Total per-sample counts of these reads ranged 74–
113 million for the FSHD versus unaffected data, and 63–72 million for the 
PMO data. Normalization factors for each sample were computed in edgeR 
with the trimmed mean of M-values normalization method, and used as 
offsets when modeling the data with negative binomial distributions with 
the function glmFit. The dispersion parameters were computed with the 
estimateGLMTagwiseDisp function, shrinking the per-gene estimates 
toward trended dispersion estimates, with prior degrees of freedom set to 
5. Likelihood-ratio tests for differential expression were performed with 
the function glmLRT. The model formula for the FSHD versus unaffected 
comparison was ~ 0 + diseaseGroup + family, and the model formula for 
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the PMO comparisons was ~ 0 + diseaseGroup:treatment + subject. Here 
the diseaseGroup factor has levels FSHD and unaffected, the treatment fac-
tor has levels FM10, control, and Opti-MEM, while the family factor and 
subject factor account for the pairings between first-degree relatives and 
between multiple treatments of subjects, respectively. To make the coef-
ficients identifiable, the sum of the coefficients for family was constrained 
to be zero in the first model, as were the sums of the coefficients for FSHD 
and unaffected subjects in the second model. The three treatments were 
modeled jointly to allow for shared estimates of dispersion parameters. 
Results for Opti-MEM were generally similar to the standard control PMO 
(e.g., Supplementary Figure S4). All subjects in the FSHD versus unaf-
fected study were female except for 14A and 14W, which were male; thus 
an additive effect for sex can be absorbed into the family factor, so it is 
not used. All subjects in the PMO study were male, except from 15V; as 
there is just one female sample we did not attempt to adjust for sex, but do 
note that the gene with the most significant change for FM10 in unaffected 
samples was XIST, which is expressed from inactivated X-chromosomes; 
this may be due to the negative-binomial model being a particularly poor 
fit for this gene, whose read count was >10,000-fold higher for the female 
unaffected subject than for the male unaffected subject, as the direction 
of change with FM10 was not consistent in the two subjects. In Figure 2, 
Supplementary Table S3 and Supplementary Figure S4 a prior count of 1 
was used in computing the log2(counts per million) and log2(fold-changes), 
to avoid infinite values; this does not affect the P-values. Approximately 
25,000 genes with zero counts in all samples (separately for the FSHD ver-
sus unaffected data and PMO data) were excluded when computing false-
discovery rates.
Some remarks on DUX4.  The DUX4 gene does not itself appear as sig-
nificantly differentially expressed in the RNA-seq comparison of FSHD 
versus unaffected myotubes (see Supplementary Table S3) or of FM10 
versus control PMO-treated FSHD myotubes (see Supplementary 
Table S2). This is due to a combination of low expression levels and nonu-
nique mapping: the GRCh37 reference genome has 10 annotated DUX4 
genes and pseudogenes on chromosome 4 (named DUX4 and DUX4L2 
to DUXL9, some but not all are 100% identical); it also includes six DUX4 
pseudogenes with over 99% homology on chromosome 10 (DUX4L10 
to DUX4L15). (Note that the Illumina iGenomes reference files do not 
include unplaced contig sequences; if these are included, the number of 
matches to reads from DUX4 may exceed the TopHat2 default value of 
20 for the “–max-multihits” option; this may also happen in the newer 
GRCh38 assembly.) Because htseq-count does not count multimapping 
reads, the DUX4 genes usually all end up with zero counts. Inspecting the 
TopHat2 alignment files, there are often a smattering of reads mapping to 
the DUX4 genes on chromosome 4, and these reads typically also map to 
between 5 and 16 other locations in the genome, depending on whether 
they fall in a region of perfect homology with the copies on chromosome 
10, and occasionally with DUX4 homologs on other chromosomes. The 
expression is low regardless of how the mapping ambiguity is resolved, 
however, as there were typically fewer than 10 paired-end reads out of 100 
million, or 0.1 fragments per million (FPM), mapping to DUX4 genes on 
chromosome 4, even for FSHD-derived myotubes. For this we used featu-
reCounts (1.5.1) (ref. 38), with options –M –p –O –s2; using –M but not 
–fraction gives full (not fractional) counts for multimapping reads, so we 
computed the FPM from counts to a single DUX4 gene, the copy named 
DUX4L2 (ENSG00000259128) that is most telomeric on chromosome 4 in 
GRCh37, although in this assembly it does not include the PAS-containing 
exon 3. Counts for the internal copy named DUX4 (ENSG00000258389) 
were nearly the same, as expected due to multimapping of the reads. Only 
myotubes derived from subject 17A had FPM > 0.11 for DUX4L2; these 
showed a reduction from 0.38 to 0.16 FPM in replicate 1, and from 0.25 
to 0.14 FPM in replicate 2, for treatment with FM10 compared with the 
standard control PMO. There were no reads mapping to DUX4 in the other 
samples in the PMO study (15A, 15U, or 17V).
Xenograft procedure and local delivery of PMO-ASO.  The Institutional 
Animal Care and Use Committee at the Johns Hopkins University School 
of Medicine approved all procedures performed in this study. NOD-
Rag1nullIL2rγnull immunodeficient mice (NRG) (Stock 007799, The Jackson 
Laboratory, Bar Harbor, ME) were used. The xenografting procedure was 
performed with biceps muscle biopsies from FSHD subjects 58A, 61A, and 
61B, as previously described.22 Human skeletal muscle xenografts which 
had fully regenerated in host NRG mice for 4–6 months were used in this 
study. For delivery of PMO-ASO, xenografts were first injected with 12 µl 
of 0.4 U/μl bovine hyaluronidase (Sigma Aldrich, Natick, MA). Xenografts 
were injected with 20 µg (1 µg /µl) of Standard Control PMO-ASO or FM10 
PMO-ASO after 2 hours. Immediately following injection, the ASO was 
electroporated using the parameters of 50 V/cm, 10 pulses at 1 Hz, and 
20 millisecond duration per pulse. Mice were euthanized 2 weeks after elec-
troporation and human xenograft muscles were collected and snap frozen 
until analysis.
SUPPLEMENTARY MATERIAL
Table S1. Morpholino sequences directed at the DUX4 transcript.
Table S2. Forty seven genes differentially expressed (with P-value 
< 10–4) in FM10 versus control PMO-treated FSHD myotubes, sorted 
by P-value.
Table S3. One hundred and twenty five genes differentially expressed 
(with P-value < 10–4) in myotubes of FSHD patients versus unaffected 
first degree relatives, sorted by P-value.
Table S4. Clinical characteristics of FSHD subjects and unaffected 
donors.
Table S5. qPCR primer sequences.
Figure S1. Effects of morpholinos on biomarker gene expression. 
Figure S2. Cell toxicity assay of FM10 morpholino conjugated to 
Peptide B (PPMO). 
Figure S3. ED50 assay of FM10 PMO. 
Figure S4. RNA-seq counts for five DUX4 targets and MYH1, a 
marker of myogenic cell differentiation.
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